SCHEMBL1837526

SCHEMBL1837526

CCC(C)Oc1ccccc1-c1cccc(P)c1-c1ccccc1OC(C)CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 3/20 0.41
APP P05067 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
KMT2A Q03164 1/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
GPBAR1 Q8TDU6 1/20 0.31
CYSLTR1 Q9Y271 1/20 0.31
DHODH Q02127 2/20 0.31
CTSA P10619 1/20 0.31
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30
ADRA2C P18825 1/20 0.30
GABRP O00591 1/20 0.30
GABRD O14764 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1836922 0.83 CA1 (0.44) MCHR1APPMEN1KMT2ACA1
SCHEMBL20829096 0.77 ADRA2A (0.48) MCHR1MEN1LMNAKMT2ADHODH
SCHEMBL1833253 0.77 ALDH1A1 (0.44) KDM4EALDH1A1HPGD
SCHEMBL8970180 0.77 MCHR1 (0.45) MCHR1MEN1LMNAKMT2AGPBAR1
SCHEMBL31490284 0.75 MCHR1 (0.51) MCHR1MEN1LMNAKMT2ACA1
SCHEMBL28161557 0.75 ADRA2A (0.48) MCHR1MEN1LMNAKMT2ADHODH
SCHEMBL476858 0.74 APP (0.57) APPMEN1KMT2ACA1CA2
SCHEMBL1835625 0.74 PDE5A (0.42) MCHR1MEN1LMNAKMT2AKDM4E
SCHEMBL1837903 0.73 CYP1A2 (0.49) MCHR1KDM4EALDH1A1
SCHEMBL30317504 0.71 CA1 (0.44) MCHR1MEN1KMT2ACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2321244-B1 IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES LLC (US) 2016-12-21 EP disclosed
US-8558030-B2 Process for telomerization of butadiene DOW GLOBAL TECHNOLOGIES LLC (US) 2013-10-15 US disclosed
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (Formerly known as Dow Global Technologies Inc.) (US) 2011-06-09 US disclosed
EP-2321244-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE Dow Global Technologies LLC (US) 2011-05-18 EP disclosed
WO-2010019360-A2 AN IMPROVED PROCESS FOR TELOMERIZATION OF BUTADIENE DOW GLOBAL TECHNOLOGIES INC. (US) 2010-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110137086-A1 PROCESS FOR TELOMERIZATION OF BUTADIENE HRH3, HRH4, TELO2 MCHR1 1473/4885APP 4178/4885MEN1 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.